share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024财年三季报
美股SEC公告 ·  11/20 02:16

Moomoo AI 已提取核心信息

FOXO Technologies Inc. (FOXO) reported a significant year-over-year increase in net revenues for the quarter ended September 30, 2024, primarily due to the acquisitions of Myrtle and RCHI. Net revenues rose to $1,196 thousand, compared to $10 thousand in the same period last year. Operating expenses decreased by 37%, with selling, general, and administrative expenses dropping by 63%. The company's net loss improved by 47%, with a net loss attributable to FOXO of $1,946 thousand. Non-operating expenses increased due to higher interest expenses. The company's liquidity position remains a concern, with a working capital deficit and total stockholders' deficit reported. FOXO continues to seek additional funding to support operations and has raised capital through various debt financings. The healthcare segment, which includes Myrtle and RCHI, contributed $1,188 thousand to net revenues, while the Labs and Life segment saw a slight decrease in revenues. The company's future performance is subject to risks including economic conditions, healthcare reforms, and the ability to attract and retain qualified healthcare professionals.
FOXO Technologies Inc. (FOXO) reported a significant year-over-year increase in net revenues for the quarter ended September 30, 2024, primarily due to the acquisitions of Myrtle and RCHI. Net revenues rose to $1,196 thousand, compared to $10 thousand in the same period last year. Operating expenses decreased by 37%, with selling, general, and administrative expenses dropping by 63%. The company's net loss improved by 47%, with a net loss attributable to FOXO of $1,946 thousand. Non-operating expenses increased due to higher interest expenses. The company's liquidity position remains a concern, with a working capital deficit and total stockholders' deficit reported. FOXO continues to seek additional funding to support operations and has raised capital through various debt financings. The healthcare segment, which includes Myrtle and RCHI, contributed $1,188 thousand to net revenues, while the Labs and Life segment saw a slight decrease in revenues. The company's future performance is subject to risks including economic conditions, healthcare reforms, and the ability to attract and retain qualified healthcare professionals.
FOXO Technologies Inc.（FOXO）报告称，截至2024年9月30日的季度净收入同比大幅增加，主要是由于收购了Myrtle和RCHI。净收入上升至$119.6万，而去年同期为$1万。营业费用减少了37％，其中销售、一般和管理费用下降了63％。公司的净亏损改善了47％，FOXO的净亏损为$194.6万。由于较高的利息支出，非营业费用增加。公司的流动性状况仍然令人担忧，报告了营运资本亏损和总股东权益亏损。FOXO继续寻求额外的资金支持运营，并通过各种债务融资筹集资金。包括Myrtle和RCHI的医疗保健部门为净收入贡献了$118.8万，而实验室和生命科学部门的收入略微下降。公司的未来业绩受到经济状况、医疗改革以及吸引和留住合格医疗专业人员的能力等风险的影响。
FOXO Technologies Inc.（FOXO）报告称，截至2024年9月30日的季度净收入同比大幅增加，主要是由于收购了Myrtle和RCHI。净收入上升至$119.6万，而去年同期为$1万。营业费用减少了37％，其中销售、一般和管理费用下降了63％。公司的净亏损改善了47％，FOXO的净亏损为$194.6万。由于较高的利息支出，非营业费用增加。公司的流动性状况仍然令人担忧，报告了营运资本亏损和总股东权益亏损。FOXO继续寻求额外的资金支持运营，并通过各种债务融资筹集资金。包括Myrtle和RCHI的医疗保健部门为净收入贡献了$118.8万，而实验室和生命科学部门的收入略微下降。公司的未来业绩受到经济状况、医疗改革以及吸引和留住合格医疗专业人员的能力等风险的影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间